Boston Scientific Co. (NYSE:BSX) Director Charles J. Dockendorff Sells 3,946 Shares of Stock

Boston Scientific Co. (NYSE:BSX) Director Charles J. Dockendorff sold 3,946 shares of the firm’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total value of $286,874.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Boston Scientific Price Performance

Shares of BSX stock opened at $72.72 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.66 and a debt-to-equity ratio of 0.47. Boston Scientific Co. has a twelve month low of $48.35 and a twelve month high of $74.39. The company has a market cap of $106.69 billion, a P/E ratio of 61.11, a P/E/G ratio of 2.51 and a beta of 0.77. The business has a fifty day simple moving average of $68.68 and a 200 day simple moving average of $61.74.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. JPMorgan Chase & Co. raised their target price on Boston Scientific from $72.00 to $82.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th. StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 16th. Royal Bank of Canada lifted their price objective on Boston Scientific from $78.00 to $82.00 and gave the stock an “outperform” rating in a research report on Thursday, April 25th. TD Cowen lifted their price objective on Boston Scientific from $65.00 to $77.00 and gave the stock an “outperform” rating in a research report on Thursday, March 7th. Finally, Mizuho lifted their price objective on Boston Scientific from $80.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. Three investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $75.09.

Hedge Funds Weigh In On Boston Scientific

Several large investors have recently bought and sold shares of BSX. Eagle Bay Advisors LLC raised its position in Boston Scientific by 542.1% in the first quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 309 shares during the last quarter. Bruce G. Allen Investments LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $28,000. RiverPark Advisors LLC acquired a new stake in shares of Boston Scientific in the first quarter valued at about $30,000. Northwest Investment Counselors LLC acquired a new stake in shares of Boston Scientific in the first quarter valued at about $31,000. Finally, Sachetta LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $32,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.